New research reveals that patients who discontinue new slimming jabs like semaglutide or tirzepatide may regain shed pounds far faster than those who stop conventional lifestyle programs.
Research printed in a leading health publication shows that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying such drugs should be cognizant of the potential of fast rebound weight gain when the therapy ends," warns expert Dr. Susan Jebb.
Such speed of regain suggests a return to starting weight in about one and a half years.
Weighing Treatments
The study, which looked at dozens of trials involving over 9,000 of patients, contrasted the outcomes of these new drugs with other pills.
The team note that people who shed pounds through diet and exercise usually experience a more gradual creep back—around 100 grams monthly—after stopping.
The Reason for the Quick Rebound
Nutrition scientists propose the mode of action of the jabs accounts for the accelerated weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of GLP-1 levels far above than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in hunger is unsuppressed, making overeating far more likely."
An Ongoing Condition?
Health authorities recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals say that, due to the high risk of relapse, the therapy is often ongoing.
This opinion is supported by drug manufacturers, who say that the findings "highlight the long-term character of excess weight," akin to managing diseases like diabetes.
User Accounts
People who have discontinued the medication report a intense return of hunger.
"It was like something flipping and you're instantly starving," recalled one woman.
This difficulty is compounded if users have not adopted permanent dietary or behavioural changes during treatment.
Widespread Adoption
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is more common among females compared to males.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, researchers emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and long-term success relies on integrated behavioural changes.